Cargando…

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study

BACKGROUND: Previous studies showed a linear correlation between partial compliance with an oral antipsychotic medication and hospitalisation risk among patients with schizophrenia. Long-acting injections (LAIs) may significantly improve adherence and reduce relapse in patients with psychosis. The a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pappa, Sofia, Mason, Katy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249591/ https://www.ncbi.nlm.nih.gov/pubmed/32547731 http://dx.doi.org/10.1177/2045125320924789

Ejemplares similares

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

PM414. The impact of long acting paliperidone palmitate on clinical outcomes and hospital stay in routine clinical practice: a UK service evaluation
por: Pappa, Sofia, et al.
Publicado: (2016)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
por: García-Carmona, Juan Antonio, et al.
Publicado: (2023)

The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study
por: Oh, So-Young, et al.
Publicado: (2019)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
por: Liu, Jie, et al.
Publicado: (2022)

Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization
por: Taylor, David, et al.
Publicado: (2014)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
por: Markovic, M.
Publicado: (2022)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)

Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance
por: Li, Kanglai, et al.
Publicado: (2021)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
por: Fernández-Miranda, Juan J., et al.
Publicado: (2021)

Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Desai, Mitesh, et al.
Publicado: (2018)

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report
por: Cicek, Erdinc, et al.
Publicado: (2017)

Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
por: Di Lorenzo, Rosaria, et al.
Publicado: (2022)

Clinical Study of Paliperidone Palmitate Long-Acting Injection Combined With Electroacupuncture in the Treatment of Methamphetamine Addicts
por: Chen, Yu, et al.
Publicado: (2021)

Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations
por: Fife, Daniel, et al.
Publicado: (2022)

Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety
por: Barnett, Joshua, et al.
Publicado: (2023)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
por: Ravenstijn, Paulien, et al.
Publicado: (2016)

PM411. Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
por: Brown, Brianne, et al.
Publicado: (2016)

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
por: Bioque, Miquel, et al.
Publicado: (2020)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study
por: Vanzetto, S., et al.
Publicado: (2022)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
por: Debaveye, Sam, et al.
Publicado: (2019)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Long-acting Paliperidone Palmitate treatment in an Ekbom’s Syndrome secondary to Lewy Body Dementia: A case report
por: Orsolini, L., et al.
Publicado: (2022)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

Alternative initiations with 6-monthly paliperidone palmitate. A descriptive study
por: Sobrino, O. C., et al.
Publicado: (2023)

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
por: Yılmaz, Enver Demirel, et al.
Publicado: (2014)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_so5cb5g1nj6rvpg646u7v7dfe9